Degrossi O J, Oliveri P, García del Río H, Labriola R, Artagaveytía D, Degrossi E B
J Nucl Med. 1985 Oct;26(10):1135-9.
We have investigated the possibilities of technetium-99m-(-3-aminohydroxypropylidene)-1-1-bisphosphon ate ([99mTc]APD) as a bone scanning agent in 14 normal subjects and 28 patients. Similar studies in the same normal subjects and patients were carried out with 99mTc-methylene-bisphosphonate ([99mTc]MDP). The compounds were labeled with 99mTc by means of an electrolytical method; the free pertechnetate content was always under 1%. The [99mTc]APD T1/2 of the third component of the disappearance plasma curve in six normal subjects was 152 +/- 46 min (mean +/- s.d.), while the 24-hr whole-body retention (WBR) was 17.6% +/- 4.6. The [99mTc]MDP value of the 24-hr WBR was 28.6% +/- 3.9 (p less than 0.001). The bone/soft-tissue ratio (B/ST) was investigated in eight control subjects on the eleventh thoracic and the fourth lumbar vertebrae. The B/ST ratios were similar for both APD and MDP studies. In 28 patients with suspected bone metastasis or primary bone disease, bone scintigraphy was carried out; both compounds showed similar findings and the same number of positive results. In five of these patients, the lesion/normal bone ratio was determined with values of 4.6 +/- 2.0 in APD studies and 4.8 +/- 2.3 with MDP. APD was also used in 126 patients; no adverse reactions were observed. The APD dose used i.v. for bone scanning was 200-fold less than those employed by mouth per day, for the treatment of bone disease for long periods. In our experience, APD appears to be an adequate agent for bone scintigraphy.
我们已在14名正常受试者和28名患者中研究了锝-99m-（-3-氨基羟基亚丙基）-1,1-双膦酸盐（[99mTc]APD）作为骨扫描剂的可能性。对相同的正常受试者和患者使用锝-99m-亚甲基二膦酸盐（[99mTc]MDP）进行了类似研究。这些化合物通过电解法用99mTc标记；游离高锝酸盐含量始终低于1%。6名正常受试者血浆消失曲线第三成分的[99mTc]APD半衰期为152±46分钟（均值±标准差），而24小时全身滞留率（WBR）为17.6%±4.6。[99mTc]MDP的24小时WBR值为28.6%±3.9（p<0.001）。在8名对照受试者的第11胸椎和第4腰椎处研究了骨/软组织比（B/ST）。APD和MDP研究的B/ST比相似。对28名疑似骨转移或原发性骨病的患者进行了骨闪烁显像；两种化合物显示出相似的结果和相同数量的阳性结果。在其中5名患者中，测定了病变/正常骨比，APD研究中的值为4.6±2.0，MDP研究中的值为4.8±2.3。APD还用于126名患者；未观察到不良反应。用于骨扫描的静脉注射APD剂量比长期口服用于治疗骨病的剂量低200倍。根据我们的经验，APD似乎是一种适用于骨闪烁显像的药物。
